Krynon, vaginal gel 90 mg/dose 1 dose 15 pcs

Progesterone is a hormone of the corpus luteum. It induces the transition of the uterine mucosa from the FSH-induced proliferation phase to the secretory phase. It reduces the excitability and contractility of the uterine muscles and fallopian tubes. Progesterone inhibits the secretion of hypothalamic release factors FSH and LH, inhibits the formation of gonadotropic hormones in the pituitary and inhibits ovulation. The progesterone in the form of a vaginal gel is incorporated into a polymeric delivery system that binds to the vaginal mucosa and guarantees a sustained release of the drug for at least 3 days.

Pharmacokinetics

Intake. When vaginal gel is administered at a dose containing 90 mg of progesterone, T< sub> max of the drug in the blood (11 ng/mL) is about 6 hours. T< sub>1/2 is 34-48 h.

Metabolism. Progesterone is metabolized mainly in the liver. Vaginal use significantly reduces the effect of first passage through the liver.

The major metabolite, 3α,5β-pregnandiol, is excreted in the urine.

Indications

Active ingredient

Composition

1 applicator contains:

Active substance:

Progesterone – 90 mg;

Associates:

Glycerol,

Light liquid paraffin,

How to take, the dosage

Intravaginal.

The maintenance of the luteal phase during assisted reproductive techniques.Starting from the day of embryo transfer, a gel of 1.125 g (90 mg of progesterone – 1 applicator) is administered daily intravaginally. If the pregnancy occurs, the therapy is continued up to 12 weeks or up to 10-12 weeks from the time of confirmed pregnancy.

Secondary amenorrhea, dysfunctional uterine bleeding caused by progesterone deficiency. 1.125 g (90 mg of progesterone) gel is administered intravaginally every other day from day 15 to day 25 of the cycle. The dose can be reduced or increased if necessary.

Hormone replacement therapy in postmenopause (in combination with estrogenic drugs). 90 mg of progesterone (1 applicator) twice a week.

Patient information for self-administration

You must follow your doctor’s recommendations exactly when using Krynon®. Crinon® contains a corpus luteum hormone identical to the natural hormone progesterone. Crinon® is injected into the vagina. For hygienic reasons and for ease of use, Krynon® is packaged in a disposable applicator, which is discarded after use.

The applicator includes an air container, flat end, top end, bottom end, and a break-off cap.

The applicator should be performed according to these instructions:

Grip the applicator by gripping the top end tightly between your thumb and forefinger. Shake the applicator like a medical thermometer so that the gel moves to the lower end of the applicator.

Hold the applicator by the top flat end of the air container, remove the break-off cap from the opposite end by twisting. Do not put pressure on the air container.

The applicator can be inserted either sitting or lying down with the knees slightly bent. Gently insert the lower end of the applicator into the vagina.

Press the air container firmly to allow the gel from the applicator to enter the vagina. Although some gel remains in the applicator, the patient receives the full dose. You can then discard the applicator with the remaining gel in it. Krynon® covers the vaginal mucosa, providing a prolonged release of progesterone.

Interaction

The use of Krynon with other intravaginal agents is not recommended.

Special Instructions

The drug Krynon contains sorbic acid, which can cause a local skin reaction (contact dermatitis).
In the course of long-term treatment regular gynecological examinations are required to rule out the possibility of endometrial hyperplasia.

In order to prevent the possibility of a “threatened” miscarriage when using Krynon, chorionic gonadotropin levels should be determined or an ultrasound examination should be performed. Use with caution if liver function is impaired. In case of sudden bleeding, as well as in case of irregular vaginal bleeding, a non-functional cause should be excluded. In case of vaginal bleeding of unclear etiology, an appropriate examination should be performed.

Because progestagens have a property of retaining fluid in the body, patients with conditions such as epilepsy, migraine, asthma, cardiovascular failure, and renal dysfunction should be monitored closely.

Patients with a history of depression should be closely monitored and treatment should be interrupted if depression worsens.

In a small number of patients receiving estrogen-progestogen therapy, decreased glucose tolerance may be observed. The mechanism of this disorder is not known. Because of this, patients with diabetes mellitus should be closely monitored during progesterone treatment.

Contraindications

Side effects

Headache, drowsiness, abdominal pain, pain in the mammary glands.

Rarely – intermenstrual bleeding, irritation of the vaginal mucosa in the place of application.

Pregnancy use

Krinon should not be used during pregnancy except for use in early pregnancy during assisted reproductive techniques.

Krinon should not be used during breastfeeding.

Similarities